SCHEMBL29549332

SCHEMBL29549332

Nc1ccccc1Nc1nc(Cl)nc2ccsc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 2/20 0.43
▸ ADORA1 P30542 2/20 0.43
▸ KDM1A O60341 1/20 0.40
▸ PDE4B Q07343 4/20 0.39
▸ PDE4A P27815 3/20 0.39
▸ PDE4C Q08493 3/20 0.39
▸ PDE4D Q08499 3/20 0.39
▸ PDE3B Q13370 2/20 0.39
▸ PDE3A Q14432 2/20 0.39
▸ GAA P10253 3/20 0.39
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ PDE7A Q13946 1/20 0.39
▸ PIM1 P11309 2/20 0.37
▸ CSNK2B P67870 2/20 0.37
▸ CSNK2A1 P68400 2/20 0.37
▸ PIM2 Q9P1W9 2/20 0.37
▸ MAPT P10636 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22828480 1.00 ADORA2A (0.43) ADORA2AADORA1KDM1APDE4BPDE4A
SCHEMBL19867253 0.81 HTT (0.45) ADORA2AADORA1PDE4BPDE4APDE4C
SCHEMBL1284289 0.80 PDE4B (0.58) ADORA2AADORA1PDE4BPDE4APDE4C
SCHEMBL19867182 0.78 ALK (0.46) ADORA2AADORA1PDE4BPDE4APDE4C
SCHEMBL25637824 0.78 PTK2 (0.54) ADORA2AADORA1PDE4BPDE4APDE4C
SCHEMBL1283919 0.75 ADORA2A (0.47) ADORA2AADORA1PDE4BPDE4APDE4C
SCHEMBL24379260 0.74 ALK (0.41) ADORA2AADORA1PDE4BPDE4APDE4C
SCHEMBL30104177 0.73 SLC22A12 (0.61) ADORA2AADORA1PDE4BPDE4APDE4C
SCHEMBL30748848 0.72 HTT (0.61) ADORA2AADORA1PDE4BPDE4APDE4C
SCHEMBL24174509 0.72 HTT (0.61) ADORA2AADORA1PDE4BPDE4APDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12365664-B2 Small molecule inhibitors of SRC tyrosine kinase DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-07-22 — — US disclosed
US-20220267294-A1 SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2022-08-25 — — US disclosed
EP-3986411-A1 SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE Dana-Farber Cancer Institute, Inc. (US) 2022-04-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12365664-B2 Small molecule inhibitors of SRC tyrosine kinase SRC, CTTN, LCK ADORA2A 4690/4885ADORA1 4785/4885KDM1A 2446/4885
US-20220267294-A1 SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE SRC, CTTN, LCK ADORA2A 4690/4885ADORA1 4785/4885KDM1A 2446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback